Preclinical News and Research

RSS

Soligenix awarded $6.4M contract to advance preclinical development of OrbeShield for GI ARS

Soligenix, Inc., a clinical stage biopharmaceutical company focused on developing products to treat inflammatory diseases and biodefense medical countermeasures where there remains an unmet medical need, announced today that it has been awarded a contract valued at up to $6.4 million by the US Department of Health and Human Service's National Institutes of Health (specifically funded by the National Institute of Allergy and Infectious Diseases or NIAID).

25 Sep 2013

University of Texas MD Anderson Cancer Center receives $48.6M grant from NCI

Broad, deep and outstanding research in cancer science, treatment and prevention have earned The University of Texas MD Anderson Cancer Center a $48.6-million, five-year grant from the National Cancer Institute and an "exceptional" ranking, the highest possible, from the NCI's extensive peer-review process.

25 Sep 2013

NCI Funds Development Of Chrysalis’ Brain Tissue Damage Treatment

The National Cancer Institute awarded Chrysalis BioTherapeutics a $1.5 million contract to continue development of Chrysalin® to mitigate radiotherapy-induced damage to normal brain tissue. The project is a collaboration between Chrysalis, Baylor College of Medicine, and the University of Texas Medical Branch (UTMB).

24 Sep 2013

Abbvie, Galapagos Ink Up To $405M CF Collaboration

...

24 Sep 2013

Rhythm starts RM-493 clinical trials in obesity patients with genetic deficiency

Rhythm announced today the initiation of the first of a series of clinical trials with RM-493, the company's novel melanocortin 4 receptor (MC4R) agonist, for the treatment of obesity in individuals with a genetic deficiency in the MC4R pathway.

24 Sep 2013

Tel Aviv University researchers develop spring-like fibers to help repair damaged heart tissue

The threat from a heart attack doesn't end with the event itself. Blockage of blood flow to the heart can cause irreversible cell death and scarring. With transplants scarce, half the people who live through a heart attack die within five years. Scientists are trying to address this problem by engineering cardiac tissue to patch up damaged areas.

24 Sep 2013

Researchers develop first imaging tool to examine myelin damage in MS

Researchers have made an exciting breakthrough - developing a first-of-its-kind imaging tool to examine myelin damage in multiple sclerosis (MS). An extremely difficult disease to diagnose, the tool will help physicians diagnose patients earlier, monitor the disease's progression, and evaluate therapy efficacy.

24 Sep 2013

Scientists validate new system for identifying individuals with preclinical Alzheimer's disease

For years, scientists have attempted to understand how Alzheimer's disease harms the brain before memory loss and dementia are clinically detectable. Most researchers think this preclinical stage, which can last a decade or more before symptoms appear, is the critical phase when the disease might be controlled or stopped, possibly preventing the failure of memory and thinking abilities in the first place.

24 Sep 2013

Avon Foundation for Women launches competition to bring emerging breast cancer technologies to market

A world-wide competition to bring emerging breast cancer technologies to market is being launched by the Avon Foundation for Women, in partnership with the National Cancer Institute (NCI), part of the NIH, and the Center for Advancing Innovation.

21 Sep 2013

Applied Integrin Sciences' drug candidate eliminates ovarian cancer tumors in pre-clinical study

Applied Integrin Sciences, Inc. announced today that its first cancer therapeutic drug candidate eliminated all intraperitoneal ovarian cancer tumors in a pre-clinical study testing a novel treatment regimen.

21 Sep 2013

UdeM's IRIC and Bristol-Myers Squibb identify small molecule drug candidate against novel target

Universit- de Montr-al and the Institute for Research in Immunology and Cancer - Commercialization of Research today announced that researchers from UdeM's Institute for Research in Immunology and Cancer and Bristol-Myers Squibb Company have jointly identified a small molecule drug candidate against a novel target.

20 Sep 2013

LCT successfully implants first patient with potential Parkinson's disease treatment

Living Cell Technologies Limited today announced that the first patient has been successfully implanted in the Phase I clinical trial of the regenerative cell therapy NTCELL – a potential treatment for Parkinson's disease.

20 Sep 2013

Orbeshield Earns Soligenix Up To $26.3M From BARDA

...

19 Sep 2013

World’s first preclinical Magnetic Particle Imaging (MPI) system announced by Bruker

At the 2013 World Molecular Imaging Congress (WMIC, www.wmicmeeting.org), Bruker today announced the world’s first Magnetic Particle Imaging (MPI) system, an entirely new technology for preclinical imaging. The addition of MPI as a complementary preclinical imaging technique for disease studies, translational research and drug discovery, has significant potential in helping researchers gain new insights into disease processes at the organ, cellular and molecular level.

From Bruker BioSpin Group 19 Sep 2013

Multimodal animal bed introduced by Bruker

Today, at the 2013 World Molecular Imaging Congress (WMIC), Bruker introduces a new multimodal animal bed enabling multiple sequential imaging sessions in preclinical research with robust repositioning between scans, while avoiding unwanted motion of the animal during the investigation. This optimizes results for image fusion, combined processing and evaluation of preclinical research applications requiring multiple imaging modalities across multiple systems.

From Bruker BioSpin Group 19 Sep 2013

ParaVision® 6 software from Bruker introduced at 2013 World Molecular Imaging Congress

At the 2013 World Molecular Imaging Congress (WMIC, www.wmicmeeting.org), Bruker today introduces its ParaVision® 6 software, setting new standards in preclinical MRI software that delivers significantly enhanced productivity for both, routine users and accomplished experts. A redefined workflow introduces optimized, application-oriented experimental protocols, an intuitive, interactive 3D scan planning viewport, and automatic reporting. Thanks to its DICOM-based data exchange module, ParaVision 6 seamlessly integrates with data from multimodal imaging studies employed in many preclinical research labs.

From Bruker BioSpin Group 19 Sep 2013

arGEN-X and Shire achieve milestone in SIMPLE Antibody R&D collaboration

arGEN-X, a clinical stage human monoclonal antibody therapeutics company, announces it has attained a key success milestone in its SIMPLE Antibody research and product development collaboration with the Human Genetic Therapies division of Shire Pharmaceuticals. The milestone, which triggered an undisclosed payment from Shire, was the first demonstration of in vivo proof of concept for one of the antibody discovery programs undertaken in the collaboration.

19 Sep 2013

Blood lipid marker may help predict risk for Parkinson's disease

A genetic mutation, known as GBA, that leads to early onset of Parkinson's disease and severe cognitive impairment (in about 4 to 7 percent of all patients with the disease) also alters how specific lipids, ceramides and glucosylceramides are metabolized. Mayo Clinic researchers have found that Parkinson's patients who do not carry the genetic mutation also have higher levels of these lipids in the blood. Further, those who had Parkinson's and high blood levels were also more likely to have cognitive impairment and dementia.

19 Sep 2013

CTI completes sale of 15,000 shares to Quogue Capital

Cell Therapeutics, Inc. today announced the closing of its previously announced sale of 15,000 shares of its Series 18 Preferred Stock directly to Quogue Capital LLC and an affiliate of Perceptive Advisors LLC in a registered direct offering conducted without an underwriter or placement agent for gross proceeds of approximately $15 million (the "Offering").

19 Sep 2013

Nanodiamonds could be used to promote bone growth and durability of dental implants

UCLA researchers have discovered that diamonds on a much, much smaller scale than those used in jewelry could be used to promote bone growth and the durability of dental implants.

19 Sep 2013

Preclinical News and Research

Soligenix awarded $6.4M contract to advance preclinical development of OrbeShield for GI ARS

University of Texas MD Anderson Cancer Center receives $48.6M grant from NCI

NCI Funds Development Of Chrysalis’ Brain Tissue Damage Treatment

Abbvie, Galapagos Ink Up To $405M CF Collaboration

Rhythm starts RM-493 clinical trials in obesity patients with genetic deficiency

Tel Aviv University researchers develop spring-like fibers to help repair damaged heart tissue

Researchers develop first imaging tool to examine myelin damage in MS

Scientists validate new system for identifying individuals with preclinical Alzheimer's disease

Avon Foundation for Women launches competition to bring emerging breast cancer technologies to market

Applied Integrin Sciences' drug candidate eliminates ovarian cancer tumors in pre-clinical study

UdeM's IRIC and Bristol-Myers Squibb identify small molecule drug candidate against novel target

LCT successfully implants first patient with potential Parkinson's disease treatment

Orbeshield Earns Soligenix Up To $26.3M From BARDA

World’s first preclinical Magnetic Particle Imaging (MPI) system announced by Bruker

Multimodal animal bed introduced by Bruker

ParaVision® 6 software from Bruker introduced at 2013 World Molecular Imaging Congress

arGEN-X and Shire achieve milestone in SIMPLE Antibody R&D collaboration

Blood lipid marker may help predict risk for Parkinson's disease

CTI completes sale of 15,000 shares to Quogue Capital

Nanodiamonds could be used to promote bone growth and durability of dental implants

New Approach Methodologies, the 3Rs and Multimodal Imaging in Preclinical Research - eBook eBook

Latest eBooks

Editorial Focus eBook - Spatial and single-cell omics (1st edition)

Industry Focus eBook - Analytical Chemistry (3rd edition)

Industry Focus eBook - Microbiome (1st edition)

Industry Focus eBook - Cell biology (5th edition)

Bringing real-time analytics to downstream bioprocess monitoring

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics